- HEARING LOSS: WHAT'S IN THE PIPELINE?
[作者:Chen, C; Lobarinas, E; Ding, D; Salvi, R,期刊:Drugs of the Future, 页码:209-227 , 文章类型: Review,,卷期:2011年36-3]
- Hearing loss due to aging, hereditary factors, noise exposure, ototoxic drugs and infection is a major healthcare problem. While the causative agents of hearing loss are diverse, many share common sequelae involving oxid...
- PROGRESS IN THE DELIVERY OF SIRNA THERAPEUTICS: POTENTIAL IN UVEAL MELANOMA
[作者:Gollob, JA; Bumcrot, D; Toudjarska, I; Bastian, BC; Sah, DW; Vaishnaw, AK,期刊:Drugs of the Future, 页码:229-239 , 文章类型: Review,,卷期:2011年36-3]
- Since 2006, when Fire and Mello were awarded the Nobel Prize in Medicine for their work on RNA interference (RNAi), there has been significant progress towards transforming what began as an important laboratory tool for ...
- VEMURAFENIB B-raf Kinase Inhibitor Oncolytic
[作者:Puzanov, I; Flaherty, KT; Sosman, JA; Grippo, JF; Su, F; Nolop, K; Lee, RJ; Bollag, G,期刊:Drugs of the Future, 页码:191-199 , 文章类型: Article,,卷期:2011年36-3]
- Vemurafenib (RG-7204, PLX-4032) is a potent inhibitor of the V600E mutation-positive B-raf kinase. Mutations in this protein have been implicated in approximately 50% of melanomas, 30-70% of thyroid tumors, 30% of serous...
|